Heron Therapeuti Net Working Capital Over Time
| HRTX Stock | USD 1.16 0.06 5.45% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Heron Therapeuti Performance and Heron Therapeuti Correlation. Heron |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeuti. If investors know Heron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heron Therapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.16) | Revenue Per Share 0.906 | Quarterly Revenue Growth 0.044 | Return On Assets (0.02) | Return On Equity (24.09) |
The market value of Heron Therapeuti is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeuti's value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeuti's market value can be influenced by many factors that don't directly affect Heron Therapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heron Therapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Working Capital Analysis
Compare Heron Therapeuti and related stocks such as Mereo BioPharma Group, Terns Pharmaceuticals, and PDS Biotechnology Corp Net Working Capital Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MREO | 53.6 M | 53.6 M | 53.6 M | 53.6 M | 53.6 M | 53.6 M | 53.6 M | 53.6 M | 18.3 M | 557 K | 21.2 M | 86.8 M | 37.5 M | 54.3 M | 42.8 M |
| TERN | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 17.3 M | 68 M | 160.1 M | 276.7 M | 255.5 M | 158.4 M |
| PDSB | 76.2 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | 29.3 M | 11.7 M | 27.1 M | 63.1 M | 66.7 M | 45.4 M | 50.2 M |
| INZY | 40.9 M | 40.9 M | 40.9 M | 40.9 M | 40.9 M | 40.9 M | 40.9 M | 40.9 M | 40.9 M | 44.2 M | 141 M | 103.7 M | 116.7 M | 181.6 M | 115.1 M |
| HOOK | 65.9 M | 65.9 M | 65.9 M | 65.9 M | 65.9 M | 65.9 M | 65.9 M | 65.9 M | 47.6 M | 113.3 M | 150.4 M | 74.5 M | 111.6 M | 105.1 M | 105 M |
| XFOR | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 29.7 M | 119.8 M | 71.4 M | 73.9 M | 106.4 M | 99.2 M | 89.4 M |
| ABOS | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 5.8 M | 38.1 M | 193.5 M | 172.5 M | 233.6 M | 141.6 M |
| DAWN | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 43.1 M | 280.7 M | 331.3 M | 345.8 M | 225.7 M |
| ELDN | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 11.7 M | 8.6 M | 113.1 M | 83.9 M | 53 M | 52.2 M | 53.5 M |
Heron Therapeuti and related stocks such as Mereo BioPharma Group, Terns Pharmaceuticals, and PDS Biotechnology Corp Net Working Capital description
My Equities
My Current Equities and Potential Positions
| Heron Therapeuti | HRTX |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.16
Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.